| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.SEMARTHRIT.2004.07.010 |
| P8608 | Fatcat ID | release_j2mg2xrrn5cm5p6s67qxcjrlam |
| P698 | PubMed publication ID | 15609262 |
| P2093 | author name string | Irene E van der Horst-Bruinsma | |
| Michael T Nurmohamed | |||
| Ben A Dijkmans | |||
| Mike J Peters | |||
| P433 | issue | 3 | |
| P921 | main subject | circulatory system | Q11068 |
| ankylosing spondylitis | Q52849 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 585-592 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Seminars in Arthritis and Rheumatism | Q15761553 |
| P1476 | title | Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis | |
| P478 | volume | 34 |
| Q95359587 | Q95359587 |
| Q43861352 | A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis |
| Q91950260 | Active ankylosing spondylitis increases blood loss during total hip arthroplasty for a stiff hip joint |
| Q46808110 | Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population |
| Q51104000 | Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. |
| Q26782184 | Ankylosing spondylitis: A state of the art factual backbone |
| Q36143588 | Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment |
| Q36059338 | Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician |
| Q30481548 | Arterial distensibility in chronic inflammatory rheumatic disorders |
| Q89417229 | Association between arterial stiffness, disease activity and functional impairment in ankylosing spondylitis patients: a cross-sectional study |
| Q36265758 | Association of Chest Pain and Risk of Cardiovascular Disease with Coronary Atherosclerosis in Patients with Inflammatory Joint Diseases |
| Q50051398 | Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis : AIP associate with cIMT in AS. |
| Q37720424 | Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis |
| Q45929978 | Atherosclerosis in Psoriatic Arthritis: A Multiparametric Analysis Using Imaging Technique and Laboratory Markers of Inflammation and Vascular Function. |
| Q38738136 | Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders |
| Q82930139 | Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab |
| Q96231881 | Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis |
| Q38898838 | Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad. |
| Q56243555 | Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study |
| Q92462247 | Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis |
| Q51769027 | Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. |
| Q34928996 | Cardiac conduction system abnormalities in ankylosing spondylitis: a cross-sectional study |
| Q57673748 | Cardiomyopathy in ankylosing spondylitis |
| Q36746588 | Cardiorespiratory fitness and cardiovascular risk in patients with ankylosing spondylitis: a cross-sectional comparative study |
| Q54255528 | Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients. |
| Q38025994 | Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights |
| Q36835851 | Cardiovascular co-morbidity in rheumatic diseases |
| Q38568465 | Cardiovascular comorbidity in rheumatic diseases |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q37808570 | Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications |
| Q38126009 | Cardiovascular risk and inflammatory rheumatic diseases |
| Q38090373 | Cardiovascular risk in juvenile idiopathic arthritis |
| Q35974962 | Cardiovascular risk in patients with psoriatic arthritis |
| Q35496549 | Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation |
| Q35788272 | Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study |
| Q38936667 | Carotid intima media thickness as a marker of atherosclerosis in ankylosing spondylitis. |
| Q82734365 | Carotid intima-media thickness and serum leptin in psoriasis |
| Q54246292 | Comorbidities in Spondyloarthritis. |
| Q38561891 | Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials |
| Q38741861 | Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism |
| Q57605596 | DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen |
| Q58694922 | Detection of high cardiovascular risk patients with ankylosing spondylitis based on the assessment of abdominal aortic calcium as compared to carotid ultrasound |
| Q38857826 | Differences in cardiovascular manifestations between ankylosing spondylitis patients with and without kyphosis |
| Q40567228 | Differential diagnosis of a patient with low back and toe pain |
| Q45940282 | Disparate effects of anti-TNF-α therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis. |
| Q37279376 | Do bisphosphonates and statins have a role in spondyloarthritis management? |
| Q40459503 | Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. |
| Q44996510 | Effect of cardiovascular training on fitness and perceived disease activity in people with ankylosing spondylitis |
| Q44204800 | Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease |
| Q51329120 | Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure. |
| Q83139265 | Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade |
| Q34072179 | Endothelial dysfunction in chronic inflammatory diseases |
| Q38124275 | Epidemiology of spondyloarthritis: a review. |
| Q54939907 | Evaluation of Right Ventricular Function by Speckle-Tracking Echocardiography in Patients with Ankylosing Spondylitis: A Case-Control Study. |
| Q39765685 | Exercise programs in trials for patients with ankylosing spondylitis: do they really have the potential for effectiveness? |
| Q38177340 | Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk |
| Q46137965 | Frequency of fragmented QRS in ankylosing spondylitis : a prospective controlled study |
| Q40651714 | Gender specific differences in patients with psoriatic arthritis |
| Q37633533 | Genomic Variant in IL-37 Confers A Significant Risk of Coronary Artery Disease. |
| Q38622217 | Golimumab for the treatment of axial spondyloarthritis |
| Q26738520 | Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials |
| Q37786627 | Golimumab: a new anti-TNF-α agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis |
| Q51491387 | High prevalence of metabolic syndrome in patients with ankylosing spondylitis. |
| Q37672346 | Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis |
| Q46416796 | Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables |
| Q54060732 | Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. |
| Q48321538 | IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents. |
| Q35638180 | Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis |
| Q34731291 | Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis--a population-based longitudinal follow-up study. |
| Q35142805 | Increased risk of ischemic stroke in young patients with ankylosing spondylitis: a population-based longitudinal follow-up study. |
| Q45108856 | Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study. |
| Q35070446 | Infliximab: 12 years of experience |
| Q40709084 | Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? |
| Q55031386 | Is triglyceride/HDL ratio a reliable screening test for assessment of atherosclerotic risk in patients with chronic inflammatory disease? |
| Q87856583 | Ischemic heart disease and ankylosing spondylitis-assessing the role of inflammation |
| Q37171871 | Issues in the treatment of ankylosing spondylitis with non-steroidal anti-inflammatory drugs |
| Q26774173 | Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis |
| Q36439889 | Management and evaluation of extra-articular manifestations in spondyloarthritis |
| Q27694518 | Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations |
| Q88310736 | Managing premature atherosclerosis in patients with chronic inflammatory diseases |
| Q36594227 | Metabolic disorders in patients with psoriasis and psoriatic arthritis |
| Q43013062 | More evidence of declining incidence of amyloidosis associated with inflammatory rheumatic diseases |
| Q38885761 | Mortality in patients with ankylosing spondylitis in Argentina |
| Q50948928 | Muscle wasting in male TNF-α blocker naïve ankylosing spondylitis patients: a comparison of gender differences in body composition. |
| Q37027264 | National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. |
| Q81786177 | Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis |
| Q38044505 | Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management |
| Q35588201 | On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study |
| Q42365374 | Patient Burden of Axial Spondyloarthritis |
| Q37956135 | Perioperative care for patients with rheumatic diseases |
| Q92464625 | Perioperative medical management for patients with RA, SPA, and SLE undergoing total hip and total knee replacement: a narrative review |
| Q41888146 | Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis |
| Q58294630 | Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study |
| Q36943007 | Predictors of Atherosclerosis in Ankylosing Spondylitis |
| Q48252795 | Prevalence of cardiovascular risk factors in patients with psoriatic arthritis |
| Q40638928 | Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. |
| Q57623452 | Prevalence of diastolic dysfunction in patients with ankylosing spondylitis: a cross-sectional study |
| Q36988417 | Psoriatic arthritis and diabetes: a population-based cross-sectional study |
| Q37051500 | Psoriatic arthritis: current topics |
| Q46172380 | Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. |
| Q39361426 | Role of Inflammatory Diseases in Hypertension |
| Q86930914 | Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis |
| Q37209974 | Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome |
| Q46087486 | Serum homocysteine level in patients with ankylosing spondylitis |
| Q47561044 | Spine and Spinal Cord Injury Associated with a Fracture in Elderly Patients with Ankylosing Spondylitis |
| Q35946169 | Spontaneous retrotransposon insertion into TNF 3'UTR causes heart valve disease and chronic polyarthritis |
| Q42956017 | Statin therapy might be beneficial for patients with ankylosing spondylitis |
| Q90397063 | The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition |
| Q50065421 | The clinical utility of human leucocyte antigen B27 in axial spondyloarthritis. |
| Q58765078 | The effect of brief versus individually tailored dietary advice on change in diet, lipids and blood pressure in patients with inflammatory joint disease |
| Q59795584 | The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis |
| Q43457089 | The electronic Psoriasis and Arthritis Screening Questionnaire (ePASQ): a sensitive and specific tool to diagnose psoriatic arthritis patients |
| Q43665850 | The impact of inflammatory rheumatic diseases on the presentation, severity, and outcome of acute coronary syndrome |
| Q35230117 | The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients |
| Q37284516 | Treatment recommendations for psoriatic arthritis. |
| Q92121586 | Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study |
| Q46468090 | Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis |
| Q33659058 | Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers |
| Q81299906 | [Frequency of cardiovascular risk factors and co-morbidity in patients with rheumatic diseases] |
| Q81141986 | [Infliximab. Role in the treatment of psoriasis] |
| Q80594483 | [Psoriasis und Psoriasis arthritis in childhood and adolescence. Overview and consensus statement of the 9th Wörlitz Expert Round Table Discussion 2006 for the Society for Child and Adolescent Rheumatology] |
| Q81241816 | [Psoriasis, metabolic syndrome and its components] |
| Q83198023 | [Susceptibility to atherosclerosis in patients with psoriasis and psoriatic arthritis as determined by carotid-femoral (aortic) pulse-wave velocity measurement] |
Search more.